Likewise, a large‐scale clinical trial has demonstrated a promising response rate and survival benefit with osimertinib in EGFR‐mutated NSCLC patients with brain metastases, with an ORR of 91% in the cEFR set and 66% in the full‐analysis set.16 This evidence concerns the gene EGFR and non-small cell lung carcinoma.